![Phase 3 EPCORE DLBCL-1 Trial for Epcoritamab Fails to Achieve Primary Endpoint</TITLE]Genmab A/S (GMAB) and AbbVie Inc. (ABBV) announced on Thursday that the Phase 3 EPCORE DLBCL-1 trial, which evaluated Epcoritamab in adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), did not meet its primary endpoint of overall survival (OS) in the United States.](https://i2.wp.com/www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?w=1024&resize=1024,1024&ssl=1 "Phase 3 EPCORE DLBCL-1 Trial for Epcoritamab Fails to Achieve Primary Endpoint</TITLE]Genmab A/S (GMAB) and AbbVie Inc. (ABBV) announced on Thursday that the Phase 3 EPCORE DLBCL-1 trial, which evaluated Epcoritamab in adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), did not meet its primary endpoint of overall survival (OS) in the United States.")
User Safety: safe
Also Read
- Phase 3 EPCORE DLBCL-1 Trial for Epcoritamab Fails to Achieve Primary Endpoint</TITLE]Genmab A/S (GMAB) and AbbVie Inc. (ABBV) announced on Thursday that the Phase 3 EPCORE DLBCL-1 trial, which evaluated Epcoritamab in adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), did not meet its primary endpoint of overall survival (OS) in the United States.
- From Gods to Quizzes: Exploring the Enduring Legacy of Greek Mythology
- Pakistani Kashmir Paralysed: Roadblocks and Internet Shutdown Isolate Poonch Region
- Nicaragua’s Parliament Votes to Cancel Elections Amid Ortega’s Directive, Sparking International Condemnation
![Eight Nations Condemn Israeli Minister Ben Gvir’s Incursion into Al-Aqsa Mosque</TITLE]](https://i0.wp.com/i.dawn.com/large/2026/07/240953519e50434.webp?w=1024&resize=1024,1024&ssl=1 "Eight Nations Condemn Israeli Minister Ben Gvir’s Incursion into Al-Aqsa Mosque</TITLE]")
